Suchergebnisse - "Asselah, Tarik"

PubPharm (32)

1

Efficacy and safety of glecaprevir/pibrentasvir in patients with HCV genotype 5/6 : An integrated analysis of phase 2/3 studies

enthalten in: Liver international : official journal of the International Association for the Study of the Liver | 2020

von Yao, B. | Fredrick, L. | Schnell, G. | +15

2

Adherence to pan-genotypic glecaprevir/pibrentasvir and efficacy in HCV-infected patients : A pooled analysis of clinical trials

enthalten in: Liver international : official journal of the International Association for the Study of the Liver | 2020

von Brown, A. | Welzel, T. | Conway, B. | +12

3

Efficacy and safety of glecaprevir/pibrentasvir in patients with chronic hepatitis C virus genotype 5 or 6 infection (ENDURANCE-5,6) : an open-label, multicentre, phase 3b trial

enthalten in: The lancet. Gastroenterology & hepatology | 2019

von Asselah, T. | Lee, S. | Yao, B. | +13

CommentIn: Lancet Gastroenterol Hepatol. 2019 Jan;4(1):5-6. - PMID 30527582

4

Safety and efficacy of glecaprevir/pibrentasvir for the treatment of chronic hepatitis C in patients aged 65 years or older

enthalten in: PloS one | 2019

von Foster, G. | Asselah, T. | Kopecky-Bromberg, S. | +5

5

Glecaprevir/pibrentasvir in patients with chronic HCV and recent drug use : An integrated analysis of 7 phase III studies

enthalten in: Drug and alcohol dependence | 2019

von Foster, G. | Dore, G. | Wang, S. | +12

6

Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without Cirrhosis

enthalten in: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association | 2018

von Asselah, T. | Kowdley, K. | Zadeikis, N. | +19

7

Glecaprevir-Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection

enthalten in: The New England journal of medicine | 2018

von Zeuzem, S. | Foster, G. | Wang, S. | +35

8

Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection : 2 Phase 3 Randomized Trials

enthalten in: Gastroenterology | 2017

von Jacobson, I. | Lawitz, E. | Gane, E. | +27

9

Ombitasvir, paritaprevir, and ritonavir plus dasabuvir for 8 weeks in previously untreated patients with hepatitis C virus genotype 1b infection without cirrhosis (GARNET) : a single-arm, open-label, phase 3b trial

enthalten in: The lancet. Gastroenterology & hepatology | 2017

von Welzel, T. | Asselah, T. | Dumas, E. | +8

CommentIn: Lancet Gastroenterol Hepatol. 2017 Jul;2(7):465-466. - PMID 28416220

10

Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection

enthalten in: The New England journal of medicine | 2017

von Bourlière, M. | Gordon, S. | Flamm, S. | +127